Astonishing advances in life sciences and biotechnology have created a whole new industry with tremendous growth potential and far reaching consequences for the way we live. A particularly exciting area where innovative research is contributing to new knowledge is reproductive health. Advances in this area will bring improvements in fertility treatments, more convenient contraceptives, novel treatments for gynecological disorders, and innovative obstetric products. Ardana was created in 2000 to meet the needs of this reproductive health market estimated to be worth Â£10.2 billion per year.	

Ardana was established to commercialize research undertaken at the Medical Research Council's Human Reproductive Sciences Unit (HRSU). The HRSU has been at the forefront of research in the human reproductive system for the last 30 years, and the unit is one of only four academic centers of excellence in human reproductive biology in the world.	

Since its inception, Ardana has raised Â£34.6 million in three funding rounds. Ardana investors include Techno Venture Management, Merlin Biosciences, MVM, ABN-AMRO Capital, 3i, ISIS Equity Partners, Scottish Widows Investment Partnership, Mitsubishi, and Green Highlander.	

Ardana is a global company in the truest sense of the word. The company, which is based in the center of Edinburgh's stunning new town, collaborates with companies across the globe. The excellence of the science undertaken at the HRSU and Ardana's close links with other local centers of excellence, such as the University of Edinburgh Department of Obstetrics and Gynecology, make Edinburgh a strong location for the company.	

BioPharm International-04-01-2004

Astonishing advances in life sciences and biotechnology have created a whole new industry with tremendous growth potential and far reaching consequences for the way we live. A particularly exciting area where innovative research is contributing to new knowledge is reproductive health. Advances in this area will bring improvements in fertility treatments, more convenient contraceptives, novel treatments for gynecological disorders, and innovative obstetric products. Ardana was created in 2000 to meet the needs of this reproductive health market estimated to be worth £10.2 billion per year.